Leiden, The Netherlands, 10 December 2024 – VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders will be in San Francisco for the Annual JP Morgan Healthcare Conference and Biotech Showcase week from 13-16 January 2025.
John Glasspool, CEO, Martijn Negen, COO and Paul Roos, CFO will be attending to engage with potential investors as part of VarmX’s ongoing Series C financing round. The team will also be there to connect with potential partners, particularly around co-development opportunities in Japan for lead asset VMX-C001, a factor Xa DOAC bypassing agent.
To meet the team whilst they are in San Francisco, please get in touch via info@varmx.com.
Notes to Editors
About VarmX
VarmX is a spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X. The compound is being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and InnovationQuarter.
For further information, please contact:
Vigo Consulting (media enquiries)
Rozi Morris
+44 20 7390 0230